U.S. markets closed
  • S&P Futures

    3,817.50
    +23.50 (+0.62%)
     
  • Dow Futures

    30,474.00
    +164.00 (+0.54%)
     
  • Nasdaq Futures

    11,719.25
    +95.50 (+0.82%)
     
  • Russell 2000 Futures

    1,780.80
    +12.80 (+0.72%)
     
  • Crude Oil

    88.29
    +0.53 (+0.60%)
     
  • Gold

    1,731.30
    +10.50 (+0.61%)
     
  • Silver

    20.83
    +0.29 (+1.42%)
     
  • EUR/USD

    0.9920
    +0.0035 (+0.36%)
     
  • 10-Yr Bond

    3.7590
    +0.1420 (+3.93%)
     
  • Vix

    28.55
    -0.52 (-1.79%)
     
  • GBP/USD

    1.1364
    +0.0042 (+0.38%)
     
  • USD/JPY

    144.5930
    -0.0170 (-0.01%)
     
  • BTC-USD

    20,333.09
    +150.27 (+0.74%)
     
  • CMC Crypto 200

    462.17
    +3.76 (+0.82%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,300.36
    +179.83 (+0.66%)
     

Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference

·1 min read
Gain Therapeutics, Inc.
Gain Therapeutics, Inc.

BETHESDA, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that members of management will participate in a fireside chat at the 2022 BTIG Biotechnology Conference on Tuesday, August 9 at 12 p.m. ET and host investor meetings. The hybrid conference will take place August 8-9 in New York City.

To listen to the live event or schedule meetings with management, please contact your BTIG representative.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com.

Investor & Media Contact:

Noor Pahlavi
Argot Partners
(212) 600-1902
Gain@argotpartners.com